Sara Byron

Title: Sara Byron: Innovator in Targeted Cancer Therapies

Introduction

Sara Byron is a prominent inventor based in Phoenix, AZ (US). She has made significant contributions to the field of cancer research, particularly in the development of targeted therapies. With a total of 3 patents, her work focuses on innovative methods for detecting and treating cancers associated with NRG1 fusion events.

Latest Patents

Sara Byron's latest patents revolve around targeted therapies for cancer. Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating patients with therapeutic agents specifically targeted to this fusion. Exemplary compositions for treating cancers with the NRG1 fusion may include therapeutic agents that inhibit Epidermal Growth Factor Receptor and/or ERBB2. These agents include cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab and pertuzumab.

Career Highlights

Throughout her career, Sara Byron has worked with esteemed organizations such as the Translational Genomics Research Institute and Queensland University of Technology. Her research has significantly advanced the understanding and treatment of cancer, particularly through her innovative approaches to targeted therapies.

Collaborations

Sara has collaborated with notable colleagues in her field, including John Carpten and David Craig. These partnerships have further enhanced her research and contributed to the development of effective cancer treatments.

Conclusion

Sara Byron is a trailblazer in the field of cancer research, with her innovative patents paving the way for new targeted therapies. Her work continues to impact the lives of patients and the scientific community alike.